48,436
edits
Difference between revisions of "GATA3"
Jump to navigation
Jump to search
m
vauthors
m (vauthors) |
|||
| Line 28: | Line 28: | ||
*[[Brenner tumour]]s and [[Walthard cell rest]]s.<ref name=pmid25281026>{{Cite journal | last1 = Roma | first1 = AA. | last2 = Masand | first2 = RP. | title = Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. | journal = Hum Pathol | volume = 45 | issue = 12 | pages = 2417-22 | month = Dec | year = 2014 | doi = 10.1016/j.humpath.2014.08.003 | PMID = 25281026 }}</ref> | *[[Brenner tumour]]s and [[Walthard cell rest]]s.<ref name=pmid25281026>{{Cite journal | last1 = Roma | first1 = AA. | last2 = Masand | first2 = RP. | title = Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. | journal = Hum Pathol | volume = 45 | issue = 12 | pages = 2417-22 | month = Dec | year = 2014 | doi = 10.1016/j.humpath.2014.08.003 | PMID = 25281026 }}</ref> | ||
*[[Malignant mesothelioma]]s (58%<ref name=pmid24145643/>). | *[[Malignant mesothelioma]]s (58%<ref name=pmid24145643/>). | ||
*Most [[T-lymphocytes]].<ref name=pmid19151747>{{cite journal | | *Most [[T-lymphocytes]].<ref name=pmid19151747>{{cite journal |authors=Ho IC, Tai TS, Pai SY |title=GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation |journal=Nat. Rev. Immunol. |volume=9 |issue=2 |pages=125–35 |date=February 2009 |pmid=19151747 |pmc=2998182 |doi=10.1038/nri2476 |url=}}</ref> Used as part of a wider panel of IHC to sub-type peripheral T-cell lymphoma, NOS.<ref name=pmid31562134>{{cite journal |authors=Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, de Leval L, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J |title=Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry |journal=Blood |volume=134 |issue=24 |pages=2159–2170 |date=December 2019 |pmid=31562134 |doi=10.1182/blood.2019000779 |url=}}</ref> | ||
*[[Skin squamous cell carcinoma]].<ref name=pmid26595821>{{cite journal | | *[[Skin squamous cell carcinoma]].<ref name=pmid26595821>{{cite journal |authors=Mertens RB, de Peralta-Venturina MN, Balzer BL, Frishberg DP |title=GATA3 Expression in Normal Skin and in Benign and Malignant Epidermal and Cutaneous Adnexal Neoplasms |journal=Am J Dermatopathol |volume=37 |issue=12 |pages=885–91 |date=December 2015 |pmid=26595821 |pmc=4894790 |doi=10.1097/DAD.0000000000000306 |url=}}</ref> | ||
===Images=== | ===Images=== | ||
| Line 36: | Line 36: | ||
==Negative== | ==Negative== | ||
*[[Prostate carcinoma]]. | *[[Prostate carcinoma]]. | ||
**Positive in benign prostate glands with radiation atypia.<ref name=pmid28316088>{{cite journal | | **Positive in benign prostate glands with radiation atypia.<ref name=pmid28316088>{{cite journal |authors=Tian W, Dorn D, Wei S, Sanders RD, Matoso A, Shah RB, Gordetsky J |title=GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall |journal=Histopathology |volume=71 |issue=1 |pages=150–155 |date=July 2017 |pmid=28316088 |doi=10.1111/his.13214 |url=}}</ref> | ||
*[[Squamous cell carcinoma of the lung]].<ref name=pmid22982890/> | *[[Squamous cell carcinoma of the lung]].<ref name=pmid22982890/> | ||